PROSPECTIVE NAMLG LD-VENEX TRIAL: AZACITIDINE IN COMBINATION WITH REDUCED DURATION OF VENETOCLAX IN PATIENTS WITH DE NOVO, SECONDARY, AND RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Library, Anne Louise Tølbøll Sørensen,
4206683
AZD0120, A DUAL BCMA/CD19 CAR-T CELL THERAPY, DEMONSTRATES A NAIVE/CENTRAL MEMORY PHENOTYPE AND INDUCES A RAPID DECLINE IN SOLUBLE BCMA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Library, Binod Dhakal,
4206741
GOLCADOMIDE (GOLCA), A POTENTIAL, FIRST-IN-CLASS, ORAL CELMOD ±RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE (PH) 1/2 STUDY LONG-TERM FOLLOW-UP (F/U)
EHA Library, Daniel Morillo,
4206781
FBEM (FLUDARABINE, BUSULFAN, ETOPOSIDE, AND MELPHALAN) CONDITIONING REGIMEN FOR PATIENTS WITH LYMPHOID MALIGNANCIES UNDERGOING ALLO-HSCT: A PROSPECTIVE PHASE II STUDY
EHA Library, Mengmeng Pan,
4206821
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ESLIM-02 FOR EFFICACY AND SAFETY OF SOVLEPLENIB (HMPL-523) IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA IN CHINA
EHA Library, Bing Han,
4206855
THE PREDIC-TO STUDY: AN INTERNATIONAL, REAL-WORLD COHORT STUDY OF VENOUS THROMBOEMBOLISM RISK MODEL STRATIFICATION IN DLBCL PATIENTS ACROSS ASIA, EUROPE, AND UNITED STATES OF AMERICA
EHA Library, Giulia Bassi,
4206891
BLOOD CANCER ASSOCIATED HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IS MORE LIKELY IN YOUNGER PATIENTS, AND ONLY AGE AND T-, NKT- AND NK-CELL LYMPHOMA DIAGNOSIS IMPACT SURVIVAL.
EHA Library, Mark Bishton,
4206927
FINAL RESULTS OF THE PHASE II S-IDE STUDY: ADDING SELINEXOR TO IFOSFAMIDE, ETOPOSIDE, AND DEXAMETHASONE DID NOT IMPROVE OUTCOMES IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMAS
EHA Library, Annalisa Chiappella,
4206932